The Department of Justice announced on June 5, 2026, that it had reached a resolution with the Cleveland Clinic Foundation requiring the health system to permanently cease offering puberty blockers, cross-sex hormones, and other gender-transition procedures to minors [1]. As part of the agreement, Cleveland Clinic agreed to pay $308,000 to resolve allegations of false billing under the False Claims Act and to dedicate $2 million toward restorative care for individuals who have detransitioned [1]. Cleveland Clinic denied all allegations underlying the settlement [1].
The False Claims Act, 31 U.S.C. § 3729 et seq., permits the federal government to pursue treble damages and civil penalties against entities that submit false or fraudulent claims for payment to federal healthcare programs. The DOJ's allegations centered on billing practices tied to gender-transition procedures performed on minors, with the government asserting those claims were improper under applicable federal reimbursement rules [1]. Ohio Attorney General Dave Yost joined the resolution alongside federal officials, underscoring the state's parallel enforcement interest [1][2]. DOJ Civil Division Principal Deputy Assistant Attorney General Brett Shumate and attorney Stanley Woodward were identified as key figures in the federal team [1].
The settlement carries an injunctive component of substantial duration: Cleveland Clinic is barred from performing or offering the covered procedures to minors for decades, a term that extends well beyond standard consent-decree time horizons [1]. The $2 million fund for detransitioners represents a structural feature not commonly seen in False Claims Act resolutions, signaling the administration's intent to attach restorative provisions to healthcare enforcement actions in this area [2]. This is the second major federal resolution targeting pediatric gender-transition care providers, following a comparable agreement with Texas Children's Hospital earlier in the administration's enforcement cycle [1].
The settlement requires no judicial approval of the False Claims Act monetary component if structured as an administrative resolution, though injunctive terms of this breadth typically invite scrutiny from affected parties and civil-liberties organizations who may seek to intervene or challenge enforceability in federal court [2]. Cleveland Clinic's denial of liability preserves its ability to contest any collateral legal consequences in subsequent proceedings. The DOJ has not publicly identified additional targets, but the pattern of sequential resolutions with major academic medical centers suggests the enforcement program remains active. Congressional oversight committees with jurisdiction over both HHS and DOJ appropriations may seek briefings on the scope of the program and the legal authority supporting the injunctive terms.